ADRENOMED
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company with a clear mission: to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. The Company’s lead product candidate is Adrecizumab, a clinical-stage, first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity to treat life-threatening conditions associated with increased vascul... ar leakage, congestion and shock. their unique treatment approach combines the therapeutic antibody with a specific diagnostic, which uses Adrenomedullin as the biomarker to identify patients. The most important target indications are sepsis and septic shock as well as acute heart failure. Adrenomed’s business is effectively secured by a strong IP position with granted patents in all major markets. Adrenomed is based in Hennigsdorf near Berlin, Germany.
ADRENOMED
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2009-01-01
Address:
Berlin, Berlin, Germany
Country:
Germany
Website Url:
http://www.adrenomed.com
Total Employee:
11+
Status:
Active
Contact:
+49 (0) 3302 20 77 8 0
Email Addresses:
[email protected]
Total Funding:
49.11 M EUR
Technology used in webpage:
Lorem Ipsum IONOS
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Basilea Pharmaceutica
Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company.
BioVersys
BioVersys is a privately held Swiss biopharmaceutical company.
Cobra Biologics
Cobra Biologics is providing a biologics and pharmaceuticals service.
Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Cytovation
Cytovation AS is a privately-held biotech company, specialising .
Hope Medicine
Hope Medicine is a science-driven clinical stage biopharmaceutical company
Molecular Partners
Molecular Partners is a clinical-stage biopharmaceutical company.
Novaremed AG
Novaremed AG is a clinical-stage Swiss biopharmaceutical company.
Current Employees Featured
Founder
Investors List
HBM Healthcare Investments
HBM Healthcare Investments investment in Convertible Note - Adrenomed
HBM Healthcare Investments
HBM Healthcare Investments investment in Convertible Note - Adrenomed
HBM Partners
HBM Partners investment in Convertible Note - Adrenomed
HBM Healthcare Investments
HBM Healthcare Investments investment in Convertible Note - Adrenomed
Wellington Partners
Wellington Partners investment in Series E - Adrenomed
HBM Healthcare Investments
HBM Healthcare Investments investment in Series E - Adrenomed
HBM Healthcare Investments
HBM Healthcare Investments investment in Convertible Note - Adrenomed
HBM Healthcare Investments
HBM Healthcare Investments investment in Series D - Adrenomed
HBM Healthcare Investments
HBM Healthcare Investments investment in Series D - Adrenomed
Wellington Partners
Wellington Partners investment in Series D - Adrenomed
Key Employee Changes
| Date | New article |
|---|---|
| 2023-02-01 | Adrenomed appoints Dr. Stephan Witte as Chief Medical Officer |
| 2022-07-12 | Adrenomed appoints David Germonpré as Chief Financial Officer |
| 2022-06-23 | Adrenomed appoints Dr. med. Steffen Stürzebecher as Chief Medical Officer |
Official Site Inspections
http://www.adrenomed.com
- Host name: 217-160-0-40.elastic-ssl.ui-r.com
- IP address: 217.160.0.40
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Adrenomed"
Adrenomed - Crunchbase Company Profile & Funding
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company with a clear mission: to rescue vascular integrity in order to save the lives of critically ill patients with limited …See details»
Adrenomed AG - LinkedIn
Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill …See details»
AdrenoMed Receives FDA Fast Track Designation for Enibarcimab …
Apr 10, 2024 Adrenomed AG Martina Kalle-Brune, Ph.D. phone: +49 (0)3302 207780 [email protected]. Media Inquiries. MC Services AG Eva Bauer / Julia von Hummel phone: …See details»
AdrenoMed AG - Drug pipelines, Patents, Clinical trials - Synapse
Explore AdrenoMed AG with its drug pipeline, therapeutic area, technology platform, 5 clinical trials, 6 news, Technology Platform:Monoclonal antibody, Drug:Adrecizumab(AdrenoMed AG).See details»
AdrenoMed Receives FDA Fast Track Designation for
Apr 10, 2024 AdrenoMed AG is a German privately financed, clinical-stage biopharmaceutical company. AdrenoMed’s mission is to rescue vascular integrity in order to save the lives of …See details»
2021 - Adrenomed
Aug 23, 2021 Weimar Sepsis Update, Sep 8-10, 2021 Adrenomed will co-host the symposium “Precision Medicine in Septic Organ Failure: Biomarker-guided Diagnosis and Therapy” on …See details»
Adrenomed AG - HBM Partners
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company with a clear mission: to rescue vascular integrity in order to save the lives of critically ill patients with limited …See details»
Adrenomed Company Profile 2024: Valuation, Funding & Investors …
Adrenomed General Information Description. Developer of clinical-stage pharmaceutical products designed to improve vascular integrity easily. The company's products use biomarker-guided …See details»
Adrenomed AG. - VentureRadar
Adrenomed AG is a privately-financed, clinical-stage biopharmaceutical company with a clear mission: to rescue vascular integrity in order to save the lives of critically ill patients with limited …See details»
Adrenomed - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Adrenomed - Overview, News & Similar companies | ZoomInfo.com
Who is Adrenomed. Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed's mission is to rescue vascular integrity and save the …See details»
Adrenomed Supervisory Board appoints Dr. Richard Jones as CEO
Mar 15, 2022 Hennigsdorf/Berlin (Germany), 15 March, 2022 – Adrenomed AG, the vascular integrity company, today announced the appointment of Dr. Richard Jones as Chief Executive …See details»
Adrenomed - Contacts, Employees, Board Members, Advisors
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company. Unlock even more features with Crunchbase ProSee details»
AdrenoMed Receives FDA Fast Track Designation for Enibarcimab …
Apr 10, 2024 Adrenomed AG. With a mortality rate of 20-30% for sepsis and 30-50% for septic shock in developed countries, sepsis represents an enormous public health burden and is …See details»
Adrenomed Company Profile - Office Locations, Competitors
Adrenomed is a clinical-stage biopharmaceutical company specializing in preserving vascular integrity in life-threatening conditions associated with increased vascular leakage, congestion, …See details»
Adrenomed Receives Positive EMA Scientific Advice for Further …
Dec 2, 2021 Adrenomed’s mission is to rescue vascular integrity and save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades …See details»
Adrenomed presents new findings on its precision medicine
Sep 8, 2023 Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of …See details»
News - Adrenomed
Oct 13, 2022 Hennigsdorf/Berlin (Germany), September 8, 2023 – Adrenomed AG, the vascular integrity company, today announced new findings on the biomarker-guided treatment of septic …See details»
2020 – Adrenomed
Sep 16, 2020 Adrenomed will participate in the virtual J.P. Morgan 39th Annual Healthcare Conference 2021. Join us for #HealthcarePartneringWeek on January 11-15, where we’ll …See details»